Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: immunohistochemical and morphometric evaluation of proliferative activity of erythro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining)
- 39 Downloads
Using monoclonal antibodies against proliferating cell nuclear antigen or PCNA (PC10) and the Ki-67 antigen (MIB1), an immunohistological and morphometric study was performed on routinely processed splenic tissue from ten patients with primary (idiopathic) osteomyelofibrosis (OMF). To determine the proliferation capacity of erythroid precursors and the endoreduplicative activity of megakaryocytes, corresponding antibodies (Ret40f and CD61) were applied in combination with the cell-cycle markers (sequential double-immunostaining). Morphometric analysis revealed no significant differences in PCNA or Ki-67 reactivity in either cell lineages. In comparison with previous studies on normal bone marrow, in splenic tissue showing myeloid metaplasia, the numbers of PCNA-labelled proerythroblasts, erythroblasts and megakaryocytes were conspicuously increased. Considering the ineffective erythropoiesis in OMF, there seemed to be a disproportional enhancement in PCNA and Ki-67 immunostaining of the red cell lineage. Similarly, the small size of megakaryocytes in advanced, OMF-associated myeloid metaplasia was in keeping with an impairment of endoreduplicative activity. In addition to various other contributory factors, anaemia in OMF may be partially caused by secondary folate (haematinic) deficiency. From experimental studies this defect is known to cause an abnormal arrest in the S-phase of the cell-cycle, comparable to that characterising pernicious anaemia. As a sequel of this pathomechanism, an undue overexpression of PCNA and Ki-67 has to be assumed, that is not necessarily associated with DNA synthesis or cell cycling.
Key wordsProliferating activity Erythroid precursors Megakaryocytes Spleen (myeloid metaplasia) PCNA Ki-67 Morphometry Primary (idiopathic) osteomyelofibrosis
Unable to display preview. Download preview PDF.
- Dervan PA, Magee HM, Buckley C, Carney DN (1992) Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 97 (Suppl 1):21–28Google Scholar
- Erber WN, Jacobs A, Oscier DC, O'Hea AM, Mason DJ (1987) Circulating micromegakaryocytes in myelodysplasia. J Clin Pathol 1349–1352Google Scholar
- Geary CG (1985) Clinical and hematological aspects of chronic myelofibrosis. In: Lewis SM (ed) Myelofibrosis, pathophysiology and clinical management. Decker, New York, pp. 15–49Google Scholar
- Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867–873PubMedGoogle Scholar
- Golick ML, Rice M (1992) Optimum staining of PCNA in paraffin sections is dependent on fixation, drying, and intensification. J Histotechnol 15:39–41Google Scholar
- Guesdon JL, Ternynck T, Avrameas S (1987) The use of avidinbiotin interaction in immunoenzymatic technics. J Histochem Cytochem 27:1131–1139Google Scholar
- Hall PA, Levison DA, Wodds AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillet CE, Camplejohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162:285–294PubMedCrossRefGoogle Scholar
- Hoffbrand AV, Chanarin I, Kremenchuzky S, Szur L, Waters AH, Mollin DL (1968) Megaloblastic anaemia in myelosclerosis. Q J Med 37:493–516Google Scholar
- Key G, Becker MHG, Baron B, Durchow M, Schlüter C, Flad HD, Gerdes J (1993) New Ki-67-equivalent murine monoclonal antibodies (MIB1–3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629–636PubMedGoogle Scholar